- Home
- APVO vs XBIO Comparison
APVO vs XBIO Comparison
Compare APVO & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- XBIO
- Stock Information
- Founded
- APVO 2016
- XBIO N/A
- Country
- APVO United States
- XBIO United States
- Employees
- APVO N/A
- XBIO N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- XBIO Health Care
- Exchange
- APVO Nasdaq
- XBIO Nasdaq
- Market Cap
- APVO 4.1M
- XBIO 4.9M
- IPO Year
- APVO N/A
- XBIO N/A
- Fundamental
- Price
- APVO $2.01
- XBIO $2.97
- Analyst Decision
- APVO Strong Buy
- XBIO Hold
- Analyst Count
- APVO 1
- XBIO 1
- Target Price
- APVO $5,920.00
- XBIO N/A
- AVG Volume (30 Days)
- APVO 134.2K
- XBIO 44.3K
- Earning Date
- APVO 08-11-2025
- XBIO 08-13-2025
- Dividend Yield
- APVO N/A
- XBIO N/A
- EPS Growth
- APVO N/A
- XBIO N/A
- EPS
- APVO N/A
- XBIO N/A
- Revenue
- APVO N/A
- XBIO $2,446,221.00
- Revenue This Year
- APVO N/A
- XBIO $10.15
- Revenue Next Year
- APVO N/A
- XBIO $11.11
- P/E Ratio
- APVO N/A
- XBIO N/A
- Revenue Growth
- APVO N/A
- XBIO N/A
- 52 Week Low
- APVO $1.72
- XBIO $2.20
- 52 Week High
- APVO $381.10
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- APVO 29.31
- XBIO 37.55
- Support Level
- APVO $1.72
- XBIO $2.63
- Resistance Level
- APVO $2.20
- XBIO $3.00
- Average True Range (ATR)
- APVO 0.18
- XBIO 0.22
- MACD
- APVO 0.01
- XBIO -0.04
- Stochastic Oscillator
- APVO 22.58
- XBIO 22.49
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.